Influenza Diagnostics Market Report
First published: 08 October 2024 | Last updated: 25 May 2026 | Report Code: influenza-diagnostics
Influenza Diagnostics Market — USD 6.5 billion in 2023, Growing to USD 13.29B by 2033 at 7.2% CAGR
This report covers a comprehensive analysis of the Influenza Diagnostics market, including key insights, market trends, and forecasts from 2023 to 2033. It presents data on market size, regional dynamics, technology innovations, and industry leaders driving future growth.
Key Takeaways
- Global market expands from $6.50 Billion in 2023 to $13.29 Billion by 2033, reflecting a 7.2% CAGR across 2023 to 2033.
- North America is largest regional market, while no single fastest-growing region is stated because regional CAGR differences remain within 0.15 percentage points.
- Europe grows from $1.96 Billion in 2023 to $4.01 Billion in 2033, supported by advanced laboratory infrastructure.
- Asia Pacific advances from $1.22 Billion in 2023 to $2.49 Billion in 2033 amid rising testing access and investment.
Influenza Diagnostics Market Report — Executive Summary
North America remains largest market by forecast-period value, while no single fastest-growing region is stated because top regional growth rates are separated by less than 0.15 percentage points. The Influenza Diagnostics Market Report examines market expansion driven by greater testing demand, technological upgrades, and heightened public health preparedness. Key factors include adoption of molecular diagnostics, increased use of rapid point-of-care tests, and investments in laboratory capacity. The report segments the market by test method, target virus, technology, and end-user, and profiles major participants such as Abbott Laboratories, Roche Diagnostics, Cepheid, Becton, Dickinson and Company, and Thermo Fisher Scientific. North America remains largest market by forecast-period value, while no single fastest-growing region is stated because top regional growth rates are separated by less than 0.15 percentage points. The research combines primary expert interviews, secondary sources, and data validation to deliver actionable insights for stakeholders assessing opportunities and competitive strategies.
Key Growth Drivers
- Rising demand for rapid and accurate influenza testing due to enhanced public health surveillance and outbreak preparedness.
- Technological advances in molecular diagnostics and point-of-care platforms improving sensitivity and turnaround times.
- Increased healthcare spending and investment in laboratory infrastructure across multiple regions.
- Regulatory and public health initiatives promoting broader testing access and integration of diagnostic solutions.
- Market activity by established diagnostics firms accelerating product development and commercialization.
| Metric | Value |
|---|---|
| Study Period | 2023 - 2033 |
| 2023 Market Size | $6.50 Billion |
| CAGR (2023-2033) | 7.2% |
| 2033 Market Size | $13.29 Billion |
| Top Companies | Abbott Laboratories, Roche Diagnostics, Cepheid, Becton, Dickinson and Company, Thermo Fisher Scientific |
| Published Date | 08 October 2024 |
| Last Modified Date | 25 May 2026 |
Influenza Diagnostics Market Overview
Customize Influenza Diagnostics Market Report market research report
- ✔ Get in-depth analysis of Influenza Diagnostics market size, growth, and forecasts.
- ✔ Understand Influenza Diagnostics's regional dynamics and industry-specific trends.
- ✔ Identify potential applications, end-user demand, and growth segments in Influenza Diagnostics
What is the Market Size & CAGR of Influenza Diagnostics Market Report market in 2023?
Influenza Diagnostics Industry Analysis
Influenza Diagnostics Market Segmentation and Scope
Tell us your focus area and get a customized research report.
Influenza Diagnostics Market Report Market Analysis Report by Region
Europe Influenza Diagnostics Market Report:
Europe grows from $1.96 Billion in 2023 to $4.01 Billion in 2033. Advanced clinical laboratories, regulatory support for testing, and investments in diagnostic tools support regional expansion.Asia Pacific Influenza Diagnostics Market Report:
Asia Pacific grows from $1.22 Billion in 2023 to $2.49 Billion in 2033. Expanding access to healthcare, rising diagnostic investments, and broader adoption of rapid testing options drive market progression.North America Influenza Diagnostics Market Report:
North America is largest regional market, rising from $2.4 Billion in 2023 to $4.91 Billion in 2033. 4 Billion in 2023, rising to $4.91 Billion in 2033. The region’s strong laboratory infrastructure, high diagnostic adoption, and active presence of major firms contribute to sustained demand and technology deployment.South America Influenza Diagnostics Market Report:
Latin America grows from $0.34 Billion in 2023 to $0.7 Billion in 2033. Growth is supported by expanding public health screening and gradual enhancement of diagnostic capabilities in clinical settings.Middle East & Africa Influenza Diagnostics Market Report:
Middle East and Africa grows from $0.58 Billion in 2023 to $1.18 Billion in 2033. Increased public health initiatives and investment in laboratory infrastructure contribute to greater testing availability.Tell us your focus area and get a customized research report.
Research Methodology
Influenza Diagnostics Market Analysis By Test Method
The market is greatly influenced by demographics in healthcare settings. Hospitals lead with a market size of $4.13 billion in 2023, expected to reach $8.43 billion by 2033, retaining a 63.48% market share. Diagnostic laboratories follow with $1.72 billion in 2023 and $3.51 billion by 2033, accounting for 26.43%. Point-of-care settings are gaining traction as rapid testing becomes increasingly vital, forecasting $0.66 billion growth to $1.34 billion by 2033.
Influenza Diagnostics Market Analysis By Target Virus
Molecular diagnostics dominate the market with a size of $5.39 billion in 2023 projected to rise to $11.02 billion by 2033, holding an impressive 82.92% share. Non-molecular diagnostics are gaining ground, with a forecast from $1.11 billion in 2023 to $2.27 billion by 2033, representing 17.08%.
Influenza Diagnostics Market Analysis By Technology
The market shows considerable reliance on rapid tests which account for $5.39 billion in 2023 and are expected to reach $11.02 billion by 2033 with an 82.92% market share. Laboratory tests represent a significant segment as well with growth projections reflecting the need for comprehensive diagnostic strategies.
Influenza Diagnostics Market Analysis By End User
Hospitals are the leading end-users of influenza diagnostics, solidifying their essential role in managing influenza outbreaks. With a market share of 63.48%, hospitals are projected to sustain the largest sector share through 2033, contrasted by diagnostic laboratories and point-of-care settings that cater to diversifying healthcare needs.
Influenza Diagnostics Market Trends and Future Forecast
Tell us your focus area and get a customized research report.
Global Market Leaders and Top Companies in Influenza Diagnostics Industry
Abbott Laboratories:
A leading player known for its rapid molecular diagnostics, Abbott’s innovative systems have revolutionized influenza testing processes.Roche Diagnostics:
Roche’s advanced diagnostics solutions, focusing on accuracy and reliability, continue to set a high standard in the influenza testing domain.Cepheid:
Specializing in molecular diagnostics, Cepheid’s revolutionary rapid tests have propelled the company to the forefront of the influenza diagnostics market.Becton, Dickinson and Company:
BD’s extensive portfolio of diagnostic products and commitment to innovation enables it to address a wide range of influenza diagnostic needs effectively.Thermo Fisher Scientific:
With a focus on cutting-edge laboratory equipment and diagnostics, Thermo Fisher plays a crucial role in enhancing influenza testing accuracy.We're grateful to work with incredible clients.
FAQs
What is the market size of the Influenza Diagnostics Market Report in 2023?
The market size in 2023 is $6.50 Billion, as reported for the Influenza Diagnostics market based on provided industry figures and regional breakdowns.
How big will the market be by 2033?
By 2033 the market is projected to reach $13.29 Billion, reflecting growth across technologies, test methods, and end-user adoption through the forecast period.
What is CAGR for the forecast period?
The compound annual growth rate for the period 2023 to 2033 is 7.2%, based on the reported expansion from 2023 to 2033 market values.
Is there a single fastest Growing region in the Influenza Diagnostics Market Report market?
No single fastest-growing region is stated for the Influenza Diagnostics Market Report market because the top regional implied CAGR values are within 0.15 percentage points of each other, making the ranking too close to call reliably.
Which companies are named as key players?
Top companies listed include Abbott Laboratories, Roche Diagnostics, Cepheid, Becton, Dickinson and Company, and Thermo Fisher Scientific as leading market participants.
What are common test Method segments covered?
Reported test-method segments include Rapid Tests and Laboratory Tests, reflecting demand for quick diagnostics and centralized laboratory-based analysis.
How big is the Europe market in 2023 and 2033?
Europe is reported at $1.96 Billion in 2023 and grows to $4.01 Billion in 2033, supported by advanced diagnostic capabilities and lab networks.
Why are molecular diagnostics important?
Molecular diagnostics are emphasized for higher sensitivity and accuracy, contributing to adoption in clinical and laboratory settings and supporting improved outbreak detection.
What is the Asia Pacific market size change?
Asia Pacific grows from $1.22 Billion in 2023 to $2.49 Billion in 2033, driven by expanding testing access and investments in diagnostic services.
Who contributed to the research methodology?
Primary interviews with industry experts and secondary research from company reports and publications supported the analysis, along with data triangulation and validation.